AMGNAmgen Inc.
Amgen Inc. (AMGN) sells biopharmaceuticals, including cholesterol-lowering drugs, osteoporosis treatments, and oncology therapies. The next catalyst is Nov 4, 2026 — Q3 2026 Earnings Release, which will provide insight into the company’s financial performance and strategic direction, including updates on key drug pipelines and revenue outlook for the quarter .
- Public fact: Amgen reported $37.41B in revenue for the 10-Q period ending June 30, 2026 .
- Scouter has modeled bull and bear paths into the next catalyst, with a lean toward the bull path.
- Past catalysts are scored in The Read, with the Q2 2026 earnings release showing a bull outcome.
The schedule
- Wed4Nov
Quarterly earnings report and guidance for Q3 2026, with focus on revenue and EPS performance.
- Tue9Feb
- Fri30Apr
Earnings report and guidance for Q1 2027, with emphasis on new drug launches and revenue growth.
- Fri23Jul
Submission of data for new drug applications, which could influence regulatory approval timelines.
- Wed4Aug
- Fri6Aug
Senior VP sells a significant amount of shares, potentially signaling a bearish outlook.
Past
- Wed5Aug
Actual outcome: Bull · $410.95 at outcome
Amgen beat EPS estimates and raised full-year revenue guidance to $38.2B–$39.4B, driven by strong growth in key products like Repatha and Evenity. The earnings report and guidance uplift fueled a rally, pushing the stock above the bull target despite a minor post-earnings pullback.
Amgen beat EPS estimates and raised full-year revenue guidance to $38.2B–$39.4B, driven by strong growth in key products like Repatha and Evenity. The earnings report and guidance uplift fueled a rally, pushing the stock above the bull target despite a minor post-earnings pullback.
- Fri13Feb
Actual outcome: Bull · $384.32 at outcome
Amgen reported a strong Q4 2025, delivering an 11.8% beat on EPS ($5.29 actual vs. $4.73 estimate), significantly exceeding analyst expectations. This fundamental outperformance, likely supported by strong momentum in the integration of Horizon assets and solid 2026 guidance, drove the stock up 13.5% immediately following the announcement. The sustained price action above the bull target confirms the bullish outcome.
Amgen reported a strong Q4 2025, delivering an 11.8% beat on EPS ($5.29 actual vs. $4.73 estimate), significantly exceeding analyst expectations. This fundamental outperformance, likely supported by strong momentum in the integration of Horizon assets and solid 2026 guidance, drove the stock up 13.5% immediately following the announcement. The sustained price action above the bull target confirms the bullish outcome.